Meeting the demand for clinically relevant neurodegenerative treatments requires a paradigm shift in how central nervous system (CNS) clinical trials have been designed and executed.
One area in which March proved to be a busy month was in Board appointments, where both Boards of Directors and Advisory Boards saw a number of interesting additions.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostrzewski, CSO at CN Bio, about single organ-on-a-chip technology.
For companies in the biotech space, it’s never been easy to navigate the legal and business risks inherent in a highly regulated, dynamic industry – and it’s only becoming more complicated
March was a light month across the board for hires news, but the digital and supplier sectors in biopharma saw a spat of notable appointments.
Editor's Picks
